Plaintiffs Claim Manufacturer's Did Not Provide Scientific Evidence to Justify Motion for Reconsideration

LOS ANGELES-Attorneys for the plaintiffs involved in a class action against the manufacturers of Paxil argue that GlaxoSmithKline's motion for reconsideration is not justified because it does not contain any new scientific evidence from the FDA that proves the drug is non-habit forming. In re: Paxil Litigation, No. 01-07937 (C.D. Calif.).

The Sept. 12 Response to the Brief of the United States of America and Opposition to GlaxoSmithKline's Motion for Reconsideration states that the FDA's letter of interest focused on federal preemption and primary jurisdiction issues rather than in-depth analysis of whether the Paxil advertisements are misleading to the …